Compare ABCB & LGND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ABCB | LGND |
|---|---|---|
| Founded | 1971 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 6.0B |
| IPO Year | 2010 | 1997 |
| Metric | ABCB | LGND |
|---|---|---|
| Price | $82.72 | $310.07 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 11 |
| Target Price | $93.00 | ★ $361.27 |
| AVG Volume (30 Days) | ★ 400.5K | 183.5K |
| Earning Date | 10-22-2026 | 10-29-2026 |
| Dividend Yield | ★ 0.97% | N/A |
| EPS Growth | 15.61 | ★ 2886.36 |
| EPS | ★ 4.13 | 0.31 |
| Revenue | N/A | ★ $141,102,000.00 |
| Revenue This Year | $5.88 | $8.82 |
| Revenue Next Year | $4.08 | $31.67 |
| P/E Ratio | ★ $19.94 | $1,024.18 |
| Revenue Growth | N/A | ★ 29.48 |
| 52 Week Low | $69.58 | $175.89 |
| 52 Week High | $93.22 | $326.63 |
| Indicator | ABCB | LGND |
|---|---|---|
| Relative Strength Index (RSI) | 52.08 | 50.75 |
| Support Level | $82.17 | $293.92 |
| Resistance Level | $86.98 | $319.83 |
| Average True Range (ATR) | 1.68 | 11.68 |
| MACD | 0.04 | -0.36 |
| Stochastic Oscillator | 30.81 | 42.92 |
Ameris Bancorp is a bank holding company that operates through Ameris Bank, its subsidiary. The company operates branches in Georgia, Alabama, Florida, and South Carolina. It offers traditional banking services such as business banking, personal banking, checking, savings, mobile banking, and others. The bank is organized into four segments: the Banking Division, the Retail Mortgage Division, the Warehouse Lending Division and the Premium Finance Division. The company generates majority of its revenue from the banking division. The company intends to acquire banks in its geographic region to increase its market share and expand beyond its current market.
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.